Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer.

Trial Profile

Study of GSK2302032A Antigen-Specific Cancer Immunotherapeutic in Patients With Resectable Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs GSK 2302032A (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 17 Aug 2016 Safety and immunogenicity results published in the Journal of Thoracic Oncology.
    • 22 Mar 2015 Status changed from completed to discontinued, according to to ClinicalTrials.gov record.
    • 14 Dec 2014 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top